

Amendments to the Claims:

Claims 1-20 (Canceled).

21. (Previously presented): Attenuated live parasite of the phylum Apicomplexa or the family of Trypanosomatidae, wherein said parasite comprises a ribosomal protein gene under the control of an inducible promoter.

22. (Previously presented): The attenuated live parasite according to Claim 21, wherein said parasite belongs to the Coccidia, the Piroplasmida or the Haemosporida.

23. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Eimeridiidae, Cryptosporidiidae or Sarcocystidae.

24. (Previously presented): The attenuated live parasite according to Claim 23, wherein said parasite belongs to the genus Eimeria, Cryptosporidium, Toxoplasma, Sarcocystis or Neospora.

25. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Babesiidae or the Theileriidae.

26. (Previously presented): The attenuated live parasite according to Claim 25, wherein said parasite belongs to the genus Babesia or Theileria.

27. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the genus Plasmodium.

28. (Previously presented): The attenuated live parasite according to Claim 21, wherein said parasite belongs to the genus Trypanosoma or the genus Leishmania

29. (Previously presented): The attenuated live parasite according to Claim 21, wherein said inducible promoter is based upon an operator site and a repressor protein capable of reversibly binding said operator site.

30. (Previously presented): The attenuated live parasite according to Claim 21, wherein said inducible promoter is inducible by antibiotics.

31. (Previously presented): The attenuated live parasite according to claim 20, wherein said inducible promoter is inducible by tetracycline or anhydrotetracyclin, or a derivative thereof.

32. (Previously presented): The attenuated live parasite according to claim 21, wherein a tetR-system is used as the inducible promoter.

33. (**Currently amended**): The attenuated live parasite according to ~~Claim 1~~, **Claim 21**,

USSN: 10/526,731

Attorney Docket: 2002.017 US

Response to Office Action of October 31, 2007

wherein said ribosomal protein gene is the gene encoding L9, S3, plastid-S9 or S13, preferably L9, S3, plastid-S9 or S13 of *Toxoplasma gondii*.

34. (Currently amended): ~~A vaccine for combating parasitic infection~~ An immunogenic composition comprising the attenuated live parasite of Claim 21 and a pharmaceutically acceptable carrier.

35. (Currently amended): A method for the production of ~~the vaccine according to Claim 34,~~ an immunogenic composition, said method comprising the mixing of ~~[[a]]~~ the live attenuated parasite according to ~~Claims 1~~ Claim 21 and a pharmaceutically acceptable carrier.

Claims 36–38 (Canceled).